What ChondroFiller injection does — and why preparation questions matter

Most patients arrive at a ChondroFiller consultation with a scan result, some joint pain, and a general sense that the injection is "the non-surgical option." That is a reasonable starting point, but it is rarely enough to evaluate whether the pathway is right for them — or to ask the questions that shape a realistic outcome.

ChondroFiller is a cell-free Type I collagen hydrogel scaffold delivered as an ultrasound-guided outpatient injection. Once placed in the joint, it gels in situ within minutes and provides a structural matrix that recruits the patient's own progenitor cells — drawn from the synovium and subchondral bone — to promote repair through a process called acellular matrix-induced chondrogenesis. There is no incision, no general anaesthesia, and no hospital admission. The biology, however, is gradual: clinical improvement is measured over months, not days, and patients who expect otherwise tend to be disappointed.

Because the suitability criteria are specific and the repair timeline is long, the questions a patient raises before agreeing to the injection matter considerably. Eligibility and imaging, procedure logistics and medications, realistic outcomes, aftercare responsibilities, and how ChondroFiller differs from other injections or surgery each open up lines of inquiry worth preparing in advance.

Whether you are a suitable candidate

Suitability for the injectable pathway is determined by a combination of imaging findings, medical history, and joint mechanics — and the first question to raise at consultation is a simple one: what exactly does the MRI show, and where does it sit on the ICRS or Outerbridge grading scale?

The grading matters because it determines which route the specialist recommends. The ultrasound-guided injection accommodates a wider range of presentations — including more advanced or diffuse joint wear — while the surgical Liquid Cartilage™ route is reserved for well-contained focal defects where the body retains sufficient regenerative capacity. If a specialist is recommending the injection over surgery, patients should ask why, and what specific features of their scan support that decision.

Entry to the injectable pathway also assumes that conservative measures have been genuinely tried. What counts as 'exhausted' conservative care varies by case — some patients will have completed a structured physiotherapy programme; others may have had viscosupplementation. Patients should ask the specialist to confirm how their own history maps against this criterion, rather than assuming prior treatment satisfies it.

Several factors may disqualify a patient outright. Active joint infection, systemic immunosuppression, poorly controlled diabetes, and unrealistic expectations of immediate or guaranteed pain relief are documented contraindications. Patients should ask the specialist to address each of these directly. It is also worth disclosing any recent corticosteroid injections, as these can affect local tissue quality and may influence the recommended timing of the procedure.

What happens on the day of the injection

On the day itself, there is no operating theatre, no fasting requirement, and no hospital admission — the appointment takes place in an outpatient clinic setting under real-time ultrasound guidance, using local anaesthesia or, in some cases, mild sedation.

Before attending, two medication questions are worth raising explicitly with the specialist. First, which agents need to be paused beforehand — blood thinners, NSAIDs, and antiplatelet therapy (including low-dose aspirin) may all require a temporary hold, and the duration differs between them. Second, patients taking aspirin for cardiovascular reasons should ask whether stopping it carries any additional risk and who should advise on that decision. These are safety questions, not administrative ones, and the answers vary by individual medication and clinical context.

Intravenous antibiotic prophylaxis is a standard component of the procedure package. Any history of antibiotic allergy — including the specific agent that caused the reaction — should be disclosed to the specialist or clinic team before the appointment date, not on arrival.

If mild sedation is being used rather than local anaesthetic alone, ask whether this introduces any restrictions on eating, drinking, or driving in advance. Even where sedation is not planned, patients should confirm whether they can drive themselves home or need to arrange transport, and whether bringing a companion is advisable.

Realistic outcomes and how long improvement takes

The clinical evaluation evidence shows average IKDC score improvements of approximately 30 points over 12 months — a meaningful shift on the scale used to measure knee function. That figure is an average across a patient population, not a prediction for any individual case; results vary by defect size, patient age, and the condition of the surrounding joint. Patients should ask the specialist what a realistic trajectory looks like for their specific scan findings rather than applying the population average to their own situation.

Complication rates in published clinical evidence are near zero, and reoperation rates sit at approximately 3–8% — more favourable than the complication rates of up to 17% and reoperation rates of up to 37% reported for ACI and MACI alternatives. That comparison is useful context, but those numbers describe populations, not individuals, and should be discussed against the patient's own clinical picture.

A defined review structure helps patients track whether the treatment is working. A six-week assessment and a 12-month evaluation are standard markers; at each point, patients should ask what measurable progress would look like. Just as importantly, they should raise the question directly: 'What would indicate this hasn't worked, and what would the next step be?' That is a question patients sometimes feel awkward asking — but a specialist should have a clear answer ready, whether it points toward further monitoring, an alternative injection pathway, or a surgical option.

Long-term data beyond 24 months for the injectable route remains limited. That gap is worth raising with the specialist, particularly for younger patients — not as a reason to decline treatment, but to understand honestly what the current evidence does and does not show about long-term durability.

Aftercare and warning signs to report

Leaving the clinic with a clear checklist matters as much as the injection itself. Same-day walking is standard — most patients go home under their own steam — but ask specifically whether any activity restriction applies for the first 24–48 hours, as individual guidance can vary.

A seven-day course of NSAIDs is typically prescribed to reduce post-injection inflammation and lower infection risk. Before the appointment ends, confirm the specific agent, dose, and whether it interacts with anything already on your regular medication list.

A discharge letter and a six-week follow-up appointment are both standard parts of the package — confirm before leaving that both are in place and that you know how to access the letter if it is sent electronically.

Ask for a direct contact number or clear written guidance covering what to watch for at home. Unexplained swelling, increasing pain, localised warmth, or spreading redness around the joint in the days after the injection are symptoms worth reporting promptly. They are uncommon — the published complication rate is near zero — but they warrant a same-day call rather than a wait-and-see approach.

Finally, ask whether physiotherapy is recommended alongside the injection, and if so, when to begin. Rehabilitation protocols after a ChondroFiller injection are not standardised across providers — this is a genuine gap in the current evidence — so the question is worth raising directly with your specialist rather than assuming a standard pathway exists.

How ChondroFiller compares to other injection options

Hyaluronic acid is the injection most patients have already tried before a ChondroFiller assessment. The two products work differently: HA acts as a lubricant and is cleared from the joint within weeks, leaving no structural change behind. A failed HA injection does not predict whether ChondroFiller will work — the mechanisms are unrelated.

Arthrosamid (polyacrylamide hydrogel, or PAAG) is a third category: a permanent, non-regenerative hydrogel designed to cushion the synovial lining and reduce pain. ChondroFiller is a temporary biodegradable scaffold that promotes endogenous repair and is gradually remodelled as progenitor cells infiltrate it. Both may appear within the same treatment strategy, but they serve different roles and neither replaces the other.

The Liquid Cartilage™ surgical route uses the same collagen scaffold material, delivered arthroscopically under general anaesthesia for well-contained focal lesions. The injectable pathway is the outpatient alternative — no theatre admission — and is suitable for a broader range of presentations, including more diffuse surface wear.

On regulatory status: ChondroFiller holds CE-marking as a Class III medical device in Europe but is not FDA-approved. Patients based outside Europe should confirm lawful access before planning treatment.

UK guide costs start from approximately £3,000 for the injectable pathway and approximately £9,800 for the Liquid Cartilage surgical route — both self-funded, private treatment. Ask the treating specialist to confirm current pricing and exactly what is included in the package, as this varies between providers. For those ready to identify a suitable UK practitioner, Search MSK lists specialists who offer ChondroFiller injection, filterable by region and specialty.